News
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million
Pentixapharm Holding AG reports a 2024 financial year loss of EUR 14 million, including risk provisions for Myelo. Find more details in the upcoming annual report -
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
Pentixapharm receives EUR 6.77 million for intangible assets formerly developed by Glycotope from undisclosed Asian pharma and biotech companies, eliminating remaining earn-out obligations -
-
-
-
COMMUNIQUÉ DE PRESSE
First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Pentixapharm starts Phase I/II trial treating leukemia with Lu177-PentixaTher, a targeted radiotherapy. Study aims to expand treatment options for hematologic malignancies
